Cargando…

Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease

Myelodysplastic syndromes (MDS) are a heterogeneous clonal disease of myeloid neoplasms characterized by ineffective hematopoiesis, variable degree of cytopenias, and an increased risk of progression to acute myeloid leukemia (AML). Molecular and genetic characterization of MDS has led to a better u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohty, Razan, Al Hamed, Rama, Bazarbachi, Ali, Brissot, Eolia, Nagler, Arnon, Zeidan, Amer, Mohty, Mohamad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429775/ https://www.ncbi.nlm.nih.gov/pubmed/36045390 http://dx.doi.org/10.1186/s13045-022-01346-9

Ejemplares similares

New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia
por: Mohty, Razan, et al.
Publicado: (2023)

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies
por: Mohty, Razan, et al.
Publicado: (2021)

Allogeneic transplant for FLT3-ITD mutated AML: a focus on FLT3 inhibitors before, during, and after transplant
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2019)

Looking Ahead: Clinical Hematology International Turns One
por: Mohty, Mohamad, et al.
Publicado: (2020)

Practicing Clinical Hematology During the COVID-19 Outbreak: A Challenge Like No Other
por: Mohty, Mohamad, et al.
Publicado: (2020)

Clinical Hematology International: Why a New Journal in Hematology?
por: Mohty, Mohamad, et al.
Publicado: (2019)

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2019)

Comprehensive Review of AL amyloidosis: some practical recommendations
por: Al Hamed, Rama, et al.
Publicado: (2021)

Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
por: Bazarbachi, Abdul Hamid, et al.
Publicado: (2022)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunobiology and Pharmacologic Manipulation of Dendritic and Regulatory Cells
por: Mohty, Mohamad, et al.
Publicado: (2013)

Current status of autologous stem cell transplantation for multiple myeloma
por: Al Hamed, Rama, et al.
Publicado: (2019)

Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
por: Brissot, Eolia, et al.
Publicado: (2020)

Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
por: Nagler, Arnon, et al.
Publicado: (2023)

Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT
por: Nagler, Arnon, et al.
Publicado: (2023)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Haploidentical Versus Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Nagler, Arnon, et al.
Publicado: (2022)

Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT
por: Munker, Reinhold, et al.
Publicado: (2017)

Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia
por: Loke, Justin, et al.
Publicado: (2022)

Arsenic trioxide induces regulatory functions of plasmacytoid dendritic cells through interferon-α inhibition
por: Ye, Yishan, et al.
Publicado: (2020)

Outbreak of OXA-48-producing Enterobacterales in a haematological ward associated with an uncommon environmental reservoir, France, 2016 to 2019
por: Jolivet, Sarah, et al.
Publicado: (2021)

Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Nagler, Arnon, et al.
Publicado: (2021)

CNS Involvement at Initial Diagnosis and Risk of Relapse After Allogeneic HCT for Acute Lymphoblastic Leukemia in First Complete Remission
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2022)

What’s Important and New in Hemochromatosis?
por: Brissot, Pierre, et al.
Publicado: (2020)

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
por: Chanias, Ioannis, et al.
Publicado: (2021)

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report
por: Nassereldine, Hasan, et al.
Publicado: (2022)

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation
por: Duléry, Rémy, et al.
Publicado: (2021)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies
por: El-Cheikh, Jean, et al.
Publicado: (2023)

Risk stratification in therapy-related myelodysplastic syndromes
por: Zeidan, Amer M.
Publicado: (2017)

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT
por: Hirschbühl, Klaus, et al.
Publicado: (2023)

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors
por: Brissot, Eolia, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
por: Hodroj, Mohammad Hassan, et al.
Publicado: (2023)

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT
por: Brissot, Eolia, et al.
Publicado: (2017)

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia
por: Al Hamed, Rama, et al.
Publicado: (2022)

Venetoclax: A New Partner in the Novel Treatment Era for Acute Myeloid Leukemia and Myelodysplastic Syndrome
por: El-Cheikh, Jean, et al.
Publicado: (2023)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ajo4al2075j933sah7k7121sk6